Management of Asthma in Adolescents and Adults

Middleton's Allergy: Principles and Practice: Eighth Edition

Volumn 1-2, Issue , 2014, Pages 902-922

  Durrani, Sandy R ^a   Busse, William W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944057682     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-08593-9.00056-5     Document Type: Chapter

References (82)

1. Szefler SJ Advancing asthma care: the glass is only half full!. J Allergy Clin Immunol 2011, 128:485-494.
2. Jackson RT, Beaglehole R, Rea HH, Sutherland DC Mortality from asthma: a new epidemic in New Zealand. BMJ 1982, 285:771-774.
3. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Expert panel report: guidelines for the diagnosis and management of asthma 1991, Department of Health and Human Services, National Institutes of Health, Bethesda, Md.
4. National Institutes of Health, National Heart, Lung, and Blood Institute, Global Initiative for Asthma. Bethesda, Md.:1995, pub. no. 95-3659.
5. National Heart, Lung, and Blood Institute http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.
6. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007, 120:S94-138.
7. Global strategy for asthma management and prevention http://www.ginasthma.org/.
8. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99. American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations.
9. Busse WW, Morgan WJ, Taggart V, Togias A Asthma outcomes workshop: overview. J Allergy Clin Immunol 2012, 129:S1-S8.
10. Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index-an outcome measure for use in children and adolescents. J Allergy Clin Immunol 2012, 129:694-701.
11. Thomas A, Lemanske RF, Jackson DJ Approaches to stepping up and stepping down care in asthmatic patients. J Allergy Clin Immunol 2011, 128:915-924.
12. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004, 351:1068-1080. Inner-City Asthma Study Group.
13. Busse WW, Lemanske RF, Gern JE Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010, 376:826-834.
14. Bel EH Smoking: a neglected cause of glucocorticoid resistance in asthma. Am J Respir Crit Care Med 2003, 168:1265-1266.
15. Crystal-Peters J, Neslusan C, Crown WH, Torres A Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002, 109:57-62.
16. Dahl R, Nielsen LP, Kips J, et al. Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. Allergy 2005, 60:875-881.
17. Lin DC, Chandra RK, Tan BK, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy 2011, 25:205-208.
18. Nordenstedt H, Nilsson M, Johansson S, et al. The relation between gastroesophageal reflux and respiratory symptoms in a population-based study: the Nord-Trøndelag health survey. Chest 2006, 129:1051-1056.
19. Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006, 173:1091-1097.
20. Harding SM Nocturnal asthma: role of nocturnal gastroesophageal reflux. Chronobiol Int 1999, 16:641-662.
21. Littner MR, Leung FW, Ballard ED, et al. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005, 128:1128-1135.
22. Camargo CA, Weiss ST, Zhang S, Willett WC, Speizer FE Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999, 159:2582-2588.
23. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181:315-323. National Heart, Lung, and Blood Institute's Severe Asthma Research Program.
24. Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012, 129:280-291.
25. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012, 67:1198-1207.
26. Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011, 128:315-322.
27. Kerstjens HA, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011, 128:308-314.
28. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010, 363:1715-1726. National Heart, Lung, and Blood Institute Asthma Clinical Research Network.
29. Westby M, Benson M, Gibson P Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004, (3).
30. Adams N, Bestall J, Jones PW Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev 2001, (1).
31. Adams NP, Bestall JC, Lasserson TJ, Jones PW Inhaled fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2005, (2).
32. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000, 106:1088-1095.
33. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999, 130:487-495.
34. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
35. Cockcroft DW, Murdock KY Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987, 79:734-740.
36. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003, 361:1071-1076.
37. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009, 179:19-24. START Investigators Group.
38. Kraft M, Cairns CB, Ellison MC, et al. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006, 130:1726-1732.
39. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997, 126:177-183.
40. Nathan RA, Bleecker ER, Kalberg C A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. Am J Med 2001, 111:195-202.
41. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011, 364:1695-1707.
42. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann Intern Med 2000, 132:97-104.
43. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005, 352:1519-1528.
44. Greening AP, Ind PW, Northfield M, Shaw G Added salmeterol versus higher-dose cortico-steroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994, 344:219-224.
45. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004, 170:836-844. GOAL Investigators Group.
46. Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005, (4).
47. Masoli M, Weatherall M, Holt S, Beasley R Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005, 60:730-734.
48. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev 2009, (4).
49. Thomas M, von Ziegenweidt J, Lee AJ, Price D High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study. J Allergy Clin Immunol 2009, 123:116-121.
50. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26. SMART Study Group.
51. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001, 285:2583-2593.
52. Lemanske RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001, 285:2594-2603. Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute.
53. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D Age and risks of FDA-approved long-acting beta(2)-adrenergic receptor agonists. Pediatrics 2011, 128:e1147-e1154.
54. Chowdhury BA, Dal Pan G The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010, 362:1169-1171.
55. Lemanske RF, Busse WW The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?. J Allergy Clin Immunol 2010, 126:449-452.
56. Sears MR, Radner F Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009, 103:1960-1968.
57. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
58. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997, 337:1405-1411.
59. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003, 58:211-216.
60. Ram FS, Cates CJ, Ducharme FM Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005, (1).
61. Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997, 337:1412-1418.
62. Kidney J, Dominguez M, Taylor PM, et al. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995, 151:1907-1914.
63. Paggiaro PL, Giannini D, Di Franco A, Testi R Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. Eur Respir J 1996, 9:1689-1695.
64. Robinson DS, Campbell D, Barnes PJ Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001, 357:2007-2011.
65. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999, 159:1043-1051.
66. Faurschou P, Steffensen I, Jacques L Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. Eur Respir J 1996, 9:1885-1890.
67. Harrison TW, Oborne J, Newton S, Tattersfield AE Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004, 363:271-275.
68. FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004, 59:550-556.
69. Rodrigo GJ, Neffen H, Castro-Rodriguez JA Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011, 139:28-35.
70. Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012, 129:983-989.
71. Johnston NW, Johnston SL, Norman GR, Dai J, Sears MR The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 2006, 117:557-562.
72. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011, 364:1005-1015.
73. Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007, 356:1327-1337.
74. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010, 181:116-124. AIR2 Trial Study Group.
75. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
76. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-1071. International Mepolizumab Study Group.
77. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N EnglJ Med 2009, 360:973-984.
78. Pavord ID, Korn S, Howarth P, et al. Mepo-lizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
79. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011, 184:1125-1132. Res-5-0010 Study Group.
80. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009, 180:388-395.
81. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
82. Viswanathan RK, Busse WW Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. Chest 2012, 141:1303-1314.